Pharmacy middlemen are working on a proposal to voluntarily change some of their business practices in an effort to avoid new regulation from the Trump administration, according to sources https://t.co/jLXcZBgMBA ...

Company Strategy - Cost Plus Drugs launched in 2022 to increase transparency in drug pricing [1] - The company aims to lower drug costs for the average consumer [1] - The company intends to disrupt the traditional pharmacy industry [1]

Pharmaceutical Industry Pressure - Faith-based activists pressured Costco regarding mifepristone availability [1] - The group is now targeting CVS and Walgreens [1] Abortion Pill (Mifepristone) - Activists are specifically concerned about the abortion pill mifepristone [1] Retail Pharmacy Implications - Pharmacies like Costco, CVS, and Walgreens are facing pressure related to abortion pill offerings [1]

Industry Pressure - Faith-based activists pressured Costco to not offer mifepristone in its pharmacy locations [1] - The group is now focusing on CVS and Walgreens [1]

Industry Pressure - Faith-based activists previously pressured Costco regarding the abortion pill mifepristone [1] - The group is now focusing on CVS and Walgreens [1]

Pharmaceutical Industry & Social Activism - Faith-based activists pressured Costco to not offer mifepristone (abortion pill) in its pharmacies [1] - The activist group is now focusing on CVS and Walgreens regarding the abortion pill mifepristone [1]

A coalition of faith-based activists had pressured Costco to not offer the abortion pill mifepristone in its pharmacy locations. The group now turns its focus to CVS and Walgreens https://t.co/onQcBjz7pU ...

Wall Street banks including JPMorgan and UBS have begun early pricing discussions with investors for a $4.25 billion debt package to help finance Sycamore Partners' buyout of UK pharmacy Boots https://t.co/VpQzXN9Bdq ...

Market Dynamics & Competitive Landscape - CVS, through its PBM (Pharmacy Benefit Manager), is preferring Wegovy over Zepbound (Lilly) due to interchangeability and leveraging its coverage of millions of lives to negotiate better economic deals [1][3] - Lilly downplays the impact, stating only about 200,000 patients will be affected [5] - The shift is happening because drugs like Wegovy and Zepbound cost about $1,000 per month [3] PBM Strategy & Negotiation - PBMs negotiate drug prices in bulk, covering potentially tens of millions of lives, to bring prices down [4][5] - The prices are confidential, but some discount is surely involved [4] - Pharmacy benefits managers negotiate prices in bulk for millions of people [4] Patient Impact & Access - Patients have been scrambling to refill prescriptions, potentially seeking 90-day supplies, due to the change [6] - Patients are trying to determine if they are still covered, can get the drug at a discounted price, or qualify for a medical exemption [6]